FOR IMMEDIATE RELEASE
Monday, May 9, 2011
Scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), report that they have developed a method—10,000 times more sensitive than other methods—to detect variant Creutzfeldt-Jacob disease (vCJD) in blood plasma. vCJD is a type of prion disease in humans that leads to brain damage and death. The NIAID researchers also used the test to rapidly detect scrapie, a prion disease of sheep, in infected hamsters, some pre-symptomatic.
Prion diseases, also known as transmissible spongiform encephalopathies, are difficult to diagnose, untreatable and ultimately fatal. Scientists believe disease-causing prions are abnormal infectious clusters of prion protein molecules. Normally, prion protein molecules exist in every mammal in an unclustered, harmless form. In prion diseases, tissue damage leaves microscopic sponge-like holes in the brain. Along with vCJD and scrapie, other forms of prion disease include chronic wasting disease in deer, elk and moose, and bovine spongiform encephalopathy, also known as mad cow disease.
Because animals and people can be infected for years before symptoms of disease appear, scientists have tried to develop a rapid and sensitive screening tool to detect prion diseases in blood, which would assist in efforts to prevent the spread of prion diseases among and between species, via the blood supply or otherwise.
Collaborating with scientists from Switzerland-based Prionics AG, the NIAID group combined an antibody-based approach with an improved real-time quaking-induced protein conversion (RT-QuIC) reaction. RT-QuIC, developed in recent years, detects when normal prion protein converts to an abnormal form. The resulting test—which they call enhanced QuIC (eQuIC)—improves prospects for routinely detecting low levels of abnormal prions in tissues, fluids or environmental samples such as soil. The group plans to study eQuIC as a potential tool to diagnose various prion diseases in different animals.
C Orru et al. Prion disease blood test using immunoprecipitation and improved quaking-induced conversion. mBio. DOI: 10.1128/mBIo.00078-11 (2011).
J Wilham et al. Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays. PLoS Pathogens 6(12): e1001217. DOI: 10.1371/journal.ppat.1001217 (2010).
Byron Caughey, Ph.D., senior investigator in the NIAID Laboratory of Persistent Viral Diseases, is available to comment on this study.
To schedule interviews, please contact Ken Pekoc, 301-402-1663, firstname.lastname@example.org.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of
infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News
releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S.
Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research,
and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH...Turning Discovery Into Health ®
back to top
Last Updated May 09, 2011
Last Reviewed May 06, 2011